Eiger BioPharmaceuticals, Inc. (EIGR) Stock Analysis

Why this analysis is different

• A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Eiger BioPharmaceuticals, Inc. (EIGR) Healthcare & Pipeline Overview

Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company dedicated to developing and commercializing targeted therapies for rare and ultra-rare diseases. Their lead candidate, Lonafarnib, is in Phase III trials for hepatitis delta virus infection, positioning them in a high-need segment of the biotechnology market.

What Is the Investment Thesis for EIGR?

Eiger BioPharmaceuticals presents a focused investment opportunity within the rare disease therapeutics market. The primary value driver is the potential approval and commercialization of Lonafarnib for hepatitis delta virus (HDV) infection, a market with significant unmet need. Positive Phase III trial results and subsequent regulatory approval could drive substantial revenue growth. The company's gross margin of 95.1% indicates strong pricing power if Lonafarnib is approved. Upcoming data readouts from ongoing clinical trials represent key catalysts. However, the company's negative profit margin of -475.3% highlights the risk of continued losses and the need for additional funding. Successful commercialization of Lonafarnib and pipeline expansion are crucial for long-term value creation.

Based on FMP financials and quantitative analysis

EIGR Key Highlights

Lonafarnib is in Phase III clinical trials targeting hepatitis delta virus (HDV) infection, a disease with limited treatment options.

• Gross margin of 95.1% suggests strong pricing power for approved products.
• The company has a pipeline of product candidates targeting rare and ultra-rare diseases, including progeria and congenital hyperinsulinism.
• Eiger BioPharmaceuticals was founded in 2008 and is headquartered in Palo Alto, California.
• The company has 56 employees, indicating a focused and lean operational structure.

Who Are EIGR's Competitors?

EIGR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are EIGR's Key Strengths?

Focus on rare and ultra-rare diseases with high unmet needs.

• Lead product candidate, Lonafarnib, in Phase III clinical trials.
• Strong gross margin potential for approved products.
• Experienced management team with expertise in drug development.

What Are EIGR's Weaknesses?

Negative profit margin and reliance on external funding.

• Dependence on the success of Lonafarnib.
• Limited commercial infrastructure compared to larger pharmaceutical companies.
• High beta of 1.84 indicates significant volatility.

What Could Drive EIGR Stock Higher?

EIGR catalyst: Data readout from Phase III clinical trials of Lonafarnib for hepatitis delta virus infection (HDV) in Q3 2026.

• Regulatory submission for Lonafarnib to the FDA and EMA in Q4 2026.
• Enrollment and progress in clinical trials for other pipeline candidates, including Lambda and Avexitide.
• Potential for strategic partnerships or collaborations to accelerate development and commercialization.

What Are the Key Risks for EIGR?

Financial-distress signal — its Altman Z-Score of -24.48 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 7 of the last 8 reported quarters.
• Clinical trial failures or negative data readouts for Lonafarnib or other pipeline candidates.
• Regulatory delays or rejection of Lonafarnib by the FDA or EMA.
• Competition from other companies developing therapies for rare diseases.
• Dependence on external funding and the need to raise additional capital.
• Patent expirations and generic competition for approved products.

What Are the Growth Opportunities for EIGR?

• Lonafarnib Commercialization: The successful commercialization of Lonafarnib for hepatitis delta virus (HDV) infection represents a major growth opportunity. HDV affects an estimated 12 million people worldwide, and there are limited treatment options. Approval by regulatory agencies, such as the FDA and EMA, could lead to significant revenue generation. The orphan drug designation for Lonafarnib could provide market exclusivity and pricing advantages. The timeline for potential approval is dependent on the outcome of Phase III trials and regulatory review, with a potential market launch within the next 2-3 years.
• Pipeline Expansion: Eiger's pipeline includes Lambda, which targets type III interferon receptors, and Avexitide for congenital hyperinsulinism. Positive clinical trial results and subsequent regulatory approvals for these candidates would diversify the company's revenue streams and reduce reliance on Lonafarnib. The market for congenital hyperinsulinism is estimated to be $500 million, offering substantial growth potential. The timeline for these programs depends on clinical trial progress and regulatory pathways.
• Geographic Expansion: Eiger currently operates in the United States and internationally. Expanding its geographic reach to additional markets, such as Europe and Asia, could increase the patient population eligible for its therapies. This would require establishing partnerships with local distributors or building a direct sales force in these regions. The timeline for geographic expansion depends on regulatory approvals and market access strategies.
• Strategic Partnerships: Eiger could pursue strategic partnerships with larger pharmaceutical companies to co-develop or commercialize its therapies. This would provide access to additional funding, expertise, and distribution networks. Partnerships could also accelerate the development of its pipeline and expand its market reach. The timing of such partnerships is uncertain and depends on the attractiveness of Eiger's assets to potential partners.
• Acquisition of New Assets: Eiger could acquire new assets or companies with complementary technologies or therapeutic areas. This would expand its pipeline and diversify its product portfolio. Potential acquisition targets could include companies developing therapies for other rare and ultra-rare diseases. The timing of acquisitions is uncertain and depends on the availability of suitable targets and the company's financial resources.

What Are EIGR's Competitive Advantages?

• Orphan drug designations provide market exclusivity and pricing power.
• Strong intellectual property protection through patents and proprietary formulations.
• Focus on rare diseases creates a niche market with less competition.
• Specialized expertise in developing therapies for rare and ultra-rare conditions.

What Does EIGR Do?

Founded in 2008 and headquartered in Palo Alto, California, Eiger BioPharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for rare and ultra-rare diseases. The company's primary focus is on addressing unmet medical needs through the development of innovative treatments. Their lead product candidate is Lonafarnib, an orally bioavailable, small molecule currently in Phase III clinical trials for the treatment of hepatitis delta virus (HDV) infection, a severe liver disease with limited treatment options. In addition to Lonafarnib, Eiger's pipeline includes Lambda, which targets type III interferon receptors and has completed Phase II clinical trials. The company is also developing Lonafarnib for the treatment of progeria and progeroid laminopathies, and Avexitide for congenital hyperinsulinism, which has completed Phase II clinical trials for post-bariatric hypoglycemia. Eiger's strategy involves identifying and developing therapies for diseases with small patient populations, often benefiting from orphan drug designations and accelerated regulatory pathways. The company operates in the United States and internationally, seeking to bring its therapies to patients worldwide.

What Products and Services Does EIGR Offer?

• Develops and commercializes targeted therapies for rare and ultra-rare diseases.
• Focuses on addressing unmet medical needs through innovative treatments.
• Conducts clinical trials to evaluate the safety and efficacy of its product candidates.
• Seeks regulatory approvals from agencies like the FDA and EMA.
• Commercializes approved therapies through its sales and marketing efforts.
• Manages intellectual property and patent protection for its products.
• Collaborates with researchers and healthcare professionals to advance its pipeline.

How Does EIGR Make Money?

• Develops pharmaceutical products focused on rare and ultra-rare diseases.
• Generates revenue through the sale of approved therapies.
• Out-licenses or partners with other companies for development and commercialization.
• Seeks orphan drug designation for its products to gain market exclusivity and pricing advantages.

What Industry Does EIGR Operate In?

Eiger BioPharmaceuticals operates within the biotechnology industry, specifically targeting the rare and ultra-rare disease market. This segment is characterized by high unmet medical needs, smaller patient populations, and the potential for orphan drug designations, which offer regulatory and commercial advantages. The competitive landscape includes companies focused on similar therapeutic areas, such as Ionis Pharmaceuticals and Ultragenyx Pharmaceutical. The market is driven by advancements in genetic research, increasing awareness of rare diseases, and regulatory incentives to develop treatments for these conditions. The global orphan drug market is projected to reach $268 billion by 2028, reflecting significant growth potential.

Who Are EIGR's Key Customers?

• Patients with rare and ultra-rare diseases.
• Healthcare providers who prescribe Eiger's therapies.
• Hospitals and clinics that administer Eiger's treatments.
• Payers, including insurance companies and government healthcare programs.

Eiger BioPharmaceuticals, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -24.48 places it in the distress zone, a signal of elevated financial risk.

Eiger BioPharmaceuticals, Inc. (EIGR) Valuation Context

Valued at $2.55M, EIGR is classified as a micro-cap stock. Relative to its peer group, EIGR's quantitative score of 54/100 is below the peer average of 77/100.

Company Profile

Eiger BioPharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Palo Alto, US. The company is led by CEO David Apelian. EIGR has traded publicly since 2014.

Eiger BioPharmaceuticals, Inc. has missed Wall Street's EPS estimate in 7 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 1781.7% below estimates on average.

Wall Street analysts project Eiger BioPharmaceuticals, Inc. revenue of about $34.4M for fiscal 2026, with EPS near $-2.70.

EIGR Financials

EIGR Latest News

No recent news available for EIGR.

EIGR Analyst Consensus

EIGR MoonshotScore

What Investors Ask About Eiger BioPharmaceuticals, Inc. (EIGR) — Healthcare

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources